国药集团从未授权药材股份及其所属企业使用国药集团和国药中药的相关字号、商标及特许经营权等无 形资产，从未允许以国药集团、国药中药名义开展任何活动，国药集团不对药材股份任何行为负责。 药材股份及其所属企业，未经授权多次擅自使用"国药集团"相关字号、商标及特许经营权，已构成严 重侵权，目前已启动法律程序，坚决追究其责任。 严正声明 国药集团 2025年10月17日 18:07 北京 10月17日， 国药集团发布声明称，集团所属中国中药有限公司（简称国药中药）已通过北京产权交易 所公开挂牌程序，将其所持国药药材股份有限公司（以下简称药材股份）25%的股权转让给上海天悦 腾华贸易服务有限公司，并于2025年9月30日在国有产权管理信息系统完成股权注销登记。 上述股权转让完成后，国药中药不再持有药材股份任何股权，国药集团、国药中药与药材股份之间不存 在任何股权关系或控制关系。 二、我集团从未授权药材股份及其所属企业使用国药集团和国药中药的相关字号、商标 及特许经营权等无形资产,从未允许以国药集团、国药中药名义开展任何活动,我们不 对药材股份任何行为负责。在此提醒社会公众和投资者在开展业务时,务必严格审核其 主体资格、资 ...

Core Viewpoint - Shandong Dongyue Future Hydrogen Energy Materials Co., Ltd. (referred to as Future Materials) has restarted its IPO process and submitted its application to the Shanghai Stock Exchange after previous attempts failed due to various issues [1][2]. Company Background - Future Materials was established in December 2017 with a registered capital of 100 million yuan, co-founded by Huaxia Shenzhou, Xinhua Group, and Beijing Xuri Xinglong, each holding 40%, 30%, and 30% respectively [1]. - The company underwent a significant change in its shareholding structure, with Dongyue Fluorosilicon Technology Group becoming the largest shareholder with a 31.21% stake [2]. Shareholding Structure - As of early 2022, the combined control of Future Materials was held by Fu Jun and his daughter Fu Shuangshuang, who together controlled 72.88% of the voting rights [3]. - Following a series of share transfers and changes in control, Zhang Jianhong regained control of Future Materials, with his entities holding a total of 36.19% of the voting rights by August 2022 [3]. Recent Developments - In June 2023, Fu Shuangshuang transferred 64% of her shares in a related entity, which has led to legal disputes regarding the validity of the transfer [4]. - The restructuring plan for Xinhua Group was approved in February 2024, leading to significant share transfers involving Future Materials [4]. Current Control - Zhang Jianhong is currently the actual controller of Future Materials, holding a total of 35.50% of the voting rights through various entities [5]. - The shareholding is relatively dispersed, with 45 shareholders as of the signing of the prospectus, and the largest shareholder being Beijing Xuri Xinglong with a 22.02% stake [9][10].